GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Rhino Biotech Ltd (OTCPK:RBRXF) » Definitions » Piotroski F-Score

Rhino Biotech (Rhino Biotech) Piotroski F-Score : 0 (As of Jun. 23, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Rhino Biotech Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rhino Biotech has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Rhino Biotech's Piotroski F-Score or its related term are showing as below:


Rhino Biotech Piotroski F-Score Historical Data

The historical data trend for Rhino Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhino Biotech Piotroski F-Score Chart

Rhino Biotech Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 1.00 2.00 2.00

Rhino Biotech Semi-Annual Data
Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 1.00 2.00 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec20) TTM:Last Year (Dec19) TTM:
Net Income was $-0.02 Mil.
Cash Flow from Operations was $-0.02 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of this year (Dec19)
to the end of this year (Dec20) was (0.002 + 0.001) / 2 = $0.0015 Mil.
Total Assets at the begining of this year (Dec19) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.04 Mil.
Total Current Assets was $0.00 Mil.
Total Current Liabilities was $0.00 Mil.
Net Income was $-0.02 Mil.

Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of last year (Dec18)
to the end of last year (Dec19) was (0.002 + 0.002) / 2 = $0.002 Mil.
Total Assets at the begining of last year (Dec18) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.04 Mil.
Total Current Assets was $0.00 Mil.
Total Current Liabilities was $0.00 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rhino Biotech's current Net Income (TTM) was -0.02. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rhino Biotech's current Cash Flow from Operations (TTM) was -0.02. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec19)
=-0.021/0.002
=-10.5

ROA (Last Year)=Net Income/Total Assets (Dec18)
=-0.02/0.002
=-10

Rhino Biotech's return on assets of this year was -10.5. Rhino Biotech's return on assets of last year was -10. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Rhino Biotech's current Net Income (TTM) was -0.02. Rhino Biotech's current Cash Flow from Operations (TTM) was -0.02. ==> -0.02 > -0.02 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Dec20
=0.041/0.0015
=27.33333333

Gearing (Last Year: Dec19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec18 to Dec19
=0.038/0.002
=19

Rhino Biotech's gearing of this year was 27.33333333. Rhino Biotech's gearing of last year was 19. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec20)=Total Current Assets/Total Current Liabilities
=0.001/0.004
=0.25

Current Ratio (Last Year: Dec19)=Total Current Assets/Total Current Liabilities
=0.002/0.003
=0.66666667

Rhino Biotech's current ratio of this year was 0.25. Rhino Biotech's current ratio of last year was 0.66666667. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Rhino Biotech's number of shares in issue this year was 34.548. Rhino Biotech's number of shares in issue last year was 34.548. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Rhino Biotech's gross margin of this year was . Rhino Biotech's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec19)
=0/0.002
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec18)
=0/0.002
=0

Rhino Biotech's asset turnover of this year was 0. Rhino Biotech's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+1+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rhino Biotech has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Rhino Biotech  (OTCPK:RBRXF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Rhino Biotech Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Rhino Biotech's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhino Biotech (Rhino Biotech) Business Description

Traded in Other Exchanges
N/A
Address
294 Heywood House, British West Indies, Anguilla, AIA
Rhino Biotech Ltd formerly Eurasia Energy Ltd is a shell company.
Executives
Nicholas W Baxter 10 percent owner 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Graham Crabtree officer: Chief Financial Officer 294 HEYWOOD HOUSE SOUTH HILL 1A AI-2640
Roger Thomas director 22 HENDERSON ROAD LONDON X0 SW18 3RR
Velda King director, officer: President, C.E.O. SUITE C102 10000 NORTH 31ST AVENUE PHOENIX AZ 85051
Gerald R Tuskey director, officer: C.F.O., Secretary/Treasurer 570 GRANVILLE STREET SUITE 400 VANCOUVER BC A1 V6C 3P1

Rhino Biotech (Rhino Biotech) Headlines

From GuruFocus

Rhino Biotech to Present at the Planet Microcap Showcase

By ACCESSWIRE ACCESSWIRE 05-04-2022